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Abstract
Objective: The objective of this systematic review is to consolidate the existing evidence on
opioid use, including administration, dosing and efficacy, for the relief of dyspnea at end-of-life.
The overarching goal is to optimize clinical management of dyspnea by identifying patterns in
opioid use, improving opioid management of dyspnea, and to prioritize future research.
Background: Opioids are commonly used in the management of dyspnea at end of life; yet
specific administration guidelines are limited. A greater understanding of the effectiveness of
opioids in relieving end-of-life dyspnea with consideration of study design, patients, and opioids,
including dyspnea evaluation tools and outcomes, will leverage development of standardized
administration and dosing.
Methods: A PRISMA guided systematic review using six databases identified quality studies of
opioid management for patients with dyspnea at end of life.
Results: Twenty-three references met review inclusion criteria which included terminally ill
cancer and non-cancer patients with various diagnoses. Studies included two randomized
controlled trials, three non-randomized experimental, three prospective observational, one
cross-sectional, and one case series. Thirteen retrospective chart reviews were also included
due to the limited rigorous studies rendered by the search. Thirteen studies evaluated
morphine, followed by fentanyl (6), oxycodone (5), general opioid use (4), and hydromorphone
(2). Routes of administration were parenteral, oral, combination, and nebulization. Dyspnea was
evaluated using self-reporting and non-self-reporting evaluation tools. Sedation was the most
reported opioid related adverse effect.
Discussion: Challenges persist in conducting end of life research preventing consensus on
standardization of opioid treatment for dyspnea within this specific palliative timeframe. Future
robust prospective trials using specific, accurate assessment with re-assessment of
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dyspnea/respiratory distress, and consideration of opioid tolerance, polypharmacy, and
comorbidities are required.
Introduction
Dyspnea is defined as “a subjective experience of breathing discomfort”, whose
presence is a strong predictor of mortality(1) and is documented as the most distressing
symptom for Intensive Care Unit (ICU) patients at high risk of dying.(2) Patients near death are
often unable to self-report this extremely distressing feeling of breathlessness.(3) Experienced
physicians, nurses and respiratory therapists often underestimate breathing discomfort in
critically ill patients.(4) Healthcare providers, caregivers, and support persons (family) report
insufficient management of respiratory distress in patients.(5) Respiratory distress is the
observed corollary to self-reported dyspnea.(6) For patients unable to self-report, respiratory
distress requires ongoing evaluation for effective symptom treatment. Similar to the
management of pain, self-reported dyspnea and observed respiratory distress have
pharmacological and non-pharmacological interventions.(7) While opioid pain management is
extensively studied, limited evidence supports the rationale, drug selection, route of
administration, dosage initiation and titration, for managing dyspnea.(8) The American Thoracic
Society has published initial dosage recommendations for parenteral and oral administration of
select opioids for patients with respiratory diseases and critical illness(9, 10) however;
recommendations specifically for end of life dyspnea management only include morphine
regimens.(11) Recommendations are administration of 5 to 10mg oral morphine or 2 to4mg of
intravenous morphine every 30 minutes as needed until respiratory comfort is achieved.(11) For
opioid tolerant patients, recommendations are to increase the morphine dose by 25 to 50%.(11)
Currently, opioid therapy is administered on an individualized basis for the palliation of
dyspnea.(1) The use of opioids in managing end-of-life respiratory distress is understudied, in
part due to the inherent fear of further hastening death.(9) While often unable to self-report,
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patients receiving palliative care at end-of-life deserve the same comfort and relief as those able
to verbalize their symptom experience.
To date, one published review examined opioid use specifically for the treatment of
dyspnea in palliative medicine. (12) This study supports ongoing use of oral and parenteral
opioids for dyspnea yet found insufficient evidence regarding the effectiveness of nebulized
opioids. Other reviews have focused exclusively on dyspnea/breathlessness in cancer
patients,(13-15) or generalized palliative treatments without specifically addressing
dyspnea.(16, 17) Evidence supports opioid administration for relief of dyspnea in cancer
patients,(13-15) (17) with no evidence for opioid management of dyspnea at end of life in
advanced heart failure.(17) There is limited evidence regarding the safety and effectiveness of
opioid pharmacotherapy for respiratory comfort to guide clinicians caring for patients at the end
of life .(16) The previous systematic review of opioids for this population was published in 2002,
therefore we aimed to consolidate the current evidence on opioid therapy including dosage,
administration and efficacy, for relief of dyspnea at end-of-life.
Methods

The reporting for this systematic review was guided by the five steps to conducting a systematic
review and PRISMA 2020 Statement.(18)
Information Sources and Search strategy
Literature searches were conducted in PubMed/MEDLINE, EMBASE, CINAHL Complete, Web
of Science, Scopus, and Cochrane Library to identify peer reviewed studies published from
January 1, 2000 to December 23, 2021. The publication dates were selected to build upon the
existing evidence of the 2002 systemic review investigating the use of opioids for dyspnea
management.(12) The research team including a medical librarian harvested a list of search
terms on three search concepts: 1) dyspnea, 2) opioids, and 3) end of life. Keywords along with
their variants, their associated medical subject headings (MeSH), Emtree terms, and CINAHL
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Complete subject headings were used for each database to identify relevant studies. The
search query was intended to apply to the title, abstract, and subject headings/keyword fields.
The complete search strategy for PubMed is given as an example in figure 1. The reference lists
of relevant studies were hand-searched to locate additional studies not captured by our
database search. The search resulted in 1831 articles. A total of 925 duplicates were removed
using Covidence systematic review software (Veritas Health Innovation, Melbourne, Australia).
Inclusion/Exclusion Criteria
Searches were designed to include all studies that might contribute data for the review
but exclude case reports, book chapters, conference abstracts and non-English publications
using build-in filters. Unpublished clinical trials, qualitative and single case studies, studies with
healthy volunteers, pediatric patients, studies not meeting our criteria for terminal stage of life,
or studies evaluating palliative sedation were also excluded during screening. Studies included
in the review were experimental, quasi-experimental, cross-sectional survey and case-series
publications examining opioid use for the relief of dyspnea in adult patients (≥ 18 years) in the
last 30 days of life. As rigorous study designs are limited in this specific area of research,
retrospective chart reviews were also included in the review. Eligible studies met the following
criteria: human, adult, and the use of fentanyl, morphine, hydromorphone or other opioids for
the relief of dyspnea at the last 30 days prior to death no matter where the care was provided.

Study selection:
Studies underwent two rounds of screening based on their (1) title and abstract and (2)
full text. In each round, studies were screened by two independent reviewers (LO and VTL),
with conflicts resolved through discussion and consensus. Both rounds of screening were
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conducted using Covidence. Twenty-three studies were selected for data extraction and
analysis. The number of included and excluded studies are reported in the PRISMA (the
Preferred Reporting Items for Systematic Reviews and Meta-Analysis) (Figure 2).
Risk of Bias
Studies were assessed individually for risk of bias. The Cochrane Risk of Bias tool (19)
was used for randomized studies, and the Risk of Bias in Nonrandomized Studies of
Interventions (ROBINS-I) (20) was used for all nonrandomized studies.

Results

A summary of included studies, including purpose/aim, opioid characteristics and dosing,
dyspnea measurements and outcomes is presented in Table 1.
Study Characteristics

The search rendered 23 publications for inclusion in the systematic review. Publication
dates were 1991 to 2020, with studies conducted in fifteen different countries, with eleven
studies from Japan and four from the United States. Studies included thirteen retrospective
chart reviews,(21-33) three non-randomized experiments,(34-37) three prospective
observational studies,(38-40) two randomized controlled trials (RCT),(41, 42) one crosssectional observational study,(37) and one case series.(43) Study sample sizes ranged from a
case series of four patients to 901 participants. All studies were conducted within inpatient or
long-term facilities, primarily under palliative services or hospice. Generally, study sites
included one to three hospital units or locations, with two exceptions, a study with sixteen sites
in Japan,(38) and a center in Palliative Care for the Elderly project, conducted in long-term care
facilities in six European countries.(37)
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Patient Characteristics

Study populations included both terminally ill advanced cancer and non-cancer patients.
Specific disease focused studies included patients with lung cancer,(36, 42) interstitial
pneumonia,(25, 31, 32) interstitial lung disease,(26) end stage congestive heart failure or
chronic obstructive pulmonary disease.(43) Studies included male and female adults up to 99
years of age.(23) Fifteen studies required patients to demonstrate adequate cognitive function
per investigator assessment (21, 25, 33, 39-41, 43) while others specified the ability of
participants to provide informed consent,(32, 34-36) communicate,(22, 38) or take oral
medications.(42) Study exclusion criteria varied; with some studies excluding patients with
chronic obstructive pulmonary disease, congestive heart failure, or renal and/or hepatic
failure,(34, 35) renal failure,(40) active or recent chemotherapy or radiation,(26, 39, 40) cancer
or focal chest lesions,(29) acute respiratory distress or those receiving codeine or fentanyl for
pain relief,(41) and a known cause of interstitial lung disease,.(32) One study enrolled only
opioid naïve patients,(33) twelve allowed both opioid tolerant and opioid naïve patients,(22, 23,
25, 30-32, 34, 35, 37-40) eight included only opioid tolerant patients,(21, 24, 27, 29, 36, 41-43)
and two studies did not report opioid tolerance.(26, 28)

Opioid Characteristics

Evaluation of Opioids and Medication Combinations

Four studies did not specify the specific types of opioids evaluated,(26-28, 41) with one
study excluding patients receiving codeine, codeine derivatives, and fentanyl for pain relief.(41)
Thirteen studies evaluated morphine,(23-25, 27, 29-32, 34, 36, 38, 40, 42) six evaluated
fentanyl,(21, 24, 30, 37, 39, 43) two evaluated hydromorphone,(34, 35) and five evaluated
oxycodone.(22, 24, 29, 33, 37) One study evaluated concomitant opioid and corticosteroid
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use.(24) Other investigations focused on opioid administration with consideration to continued
medical treatments potentially affecting dyspnea severity including diuretics, steroids,
antibiotics, benzodiazepines, oxygen delivery, or blood transfusion. Seven studies reported
concurrent oxygen use by varying delivery methods.(21, 22, 25, 31-34)

Routes of Administration and Dosing

The most frequent route of administration was parenteral, followed by oral, a
combination of routes, and nebulization. Routes of administration with specific dosing regimens
are included in Table 1. Four studies did not specify the route(s) of opioid administration.(26, 28,
30, 37) Of the remaining nineteen studies, five evaluated intravenous administration,(23, 31,
33, 36, 39) two used subcutaneous administration,(22, 25) and two included a combination of
these routes.(21, 38) Three studies included solely oral administration,(27, 34, 35) one oral and
intravenous,(32) and two oral and subcutaneous.(41, 42) One study evaluated a nebulized
opioid, (40) and one study evaluated the oral transmucosal route.(43) The remaining two
investigations evaluated a combination of routes, one examining oral, intravenous and
transdermal, with the second examining oral, parenteral, and rectal administration.(24, 29) The
studies evaluated a variety of opioid dosing regimens (Table 1.).

Single opioid dose administration: The efficacy of a single dose of opioid for relief of
dyspnea was evaluated in two studies with initial dosage based on one-quarter or one-half of
the equivalent of a prior four hour analgesic opioid dose(41) or one-twelfth of a prior 24 hour
opioid analgesic dose.(42)

Continuous/multiple-dose opioid administration: Two studies initiated continuous low
dose morphine intravenous infusion for the relief of dyspnea, at 0.25 mg/hr.(25, 38) This initial
morphine dose was used for opioid-naïve patients in both studies with the exception of opioid-
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While the second study

did not report opioid tolerance, four of the twenty-five participants received codeine prior to
hospitalization.(25)

Other parenteral morphine studies based initial dosages on 50% of the

total bolus dose required for respiratory comfort,(36) or a mean starting dose of 3.3mg/hr.(23)
Parenteral fentanyl studies were initiated based on the participants previous opioid treatment
with an addition of 30-50%,(21) or at 5-25mcg/hr for fentanyl responders, and 5-35mcg/hr for
fentanyl non-responders.(39) Studies with intravenous oxycodone reported an initial median
dose of 6mg/day,(33) and a mean daily basal subcutaneous infusion dose of 25.1mg/day.(22)

One study used transmucosal fentanyl, initiated at 200mcg per dose.(43) Oral
hydromorphone was initiated based on the patient’s initial dyspnea intensity as well as
performance status, and titrated every four hours by either 0.5mg (35) or doubled as
needed,(34) and oral morphine was initiated at 3mg every four hours.(44) Nebulized morphine
was initiated at 20mg.(40)

Opioid dosage was not consistently reported for all studies,(24, 26, 28, 30, 37) or was
reported as an initial oral morphine 50 mg equivalent,(27) or equivalent mean daily dose of 7.3
mg intravenous morphine.(32) For studies using opioid titration regimens, dosing titration
occurred every 4 to 48 hours based on the patients’ respiratory status, respiratory comfort, and
level of sedation. Seven studies included breakthrough dosing,(21-23, 34-36, 41) calculating
the dose per usual care,(41) as a percentage or fraction of the total daily opioid dose
administered every 15 to30 minutes as needed,(21, 34, 35) or using an unspecified regimen.

Adverse Effects

Ten of the twenty-three studies did not report any opioid associated adverse effects.(23,
24, 26-28, 30, 35, 37, 38, 41) No significant adverse effects e.g. respiratory depression,
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excessive sedation, myoclonus, intercostal rigidity, pruritus, or gastrointestinal effects were
documented with transmucosal fentanyl use.(43) Morphine oral or subcutaneous administration
was without documented adverse effects in one study.(42)

Respiratory depression: Studies using low dose parenteral morphine,(25) oral
morphine or hydromorphone reported no decrease in respiratory rate with these opioids.(34)
Respiratory depression with continuous morphine infusion resolved after the infusion rate (dose)
was reduced by half in one study.(30) Sedation: Sedation was reported as a major side effect
for intravenous morphine.(31, 36) In one study sedation was managed by temporarily
discontinuing the infusion and then restarting at half the dose.(36) In the same study, all
patients experienced drowsiness and two patients, both with squamous cell carcinoma (lung)
diagnoses, received naloxone for severe sedation.(36) Other adverse effects: Delirium,(31, 32)
hypercapnia, hypotension, malaise, decreased level of consciousness(32) were reported during
continuous morphine infusions. Hemoptysis of uncertain morphine causality, bitter taste, and
mask claustrophobia were reported with nebulized morphine;(40). Parenteral oxycodone
administration was frequently associated with drowsiness or somnolence,(22, 33) and to a
lesser extent, delirium, pruritus, nausea, urinary retention, consciousness disturbance, and
respiratory depression.(22) Parenteral fentanyl administration was well tolerated without
serious adverse effects in one study,(18) however a second study documented myoclonic jerks,
pruritus (6.3%), nausea, vomiting and nightmares (12.5%).(39)

Dyspnea Measurement

Dyspnea Outcome Reporting
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Dyspnea was evaluated in all included studies. Three studies evaluated opioid use for
dyspnea along with pain relief in the context of comfort care.(23, 27, 37) Another study
evaluated a combination of symptoms ; dyspnea, loss of consciousness, cough, sputum,
fatigue, delirium, insomnia, anorexia and pain.(26) One study evaluated the multidimensional
nature of dyspnea, including etiology and concomitant symptoms. (30) The third study was
exploratory reporting a range of treatment outcomes which included respiratory rates and Borg
scores.(32)

Dyspnea Assessment

Dyspnea measurement tools used in the studies were for self-reporting patients, with
few studies including non-self-report or proxy report. Self-report tools included: Visual Analog
Scale (VAS),(22, 40-43) four-point scale,(21) Numeric Rating Scale (NRS),(22, 25, 34, 35) zero
to two relief scale,(36) Modified Borg Scale,(32) Palliative Care Outcomes Collaboration
(PCOC),(30) mild-severe categorical scale,(39) ad hoc symptom rating scale,(31) and the
Dyspnoea Assessment Questionnaire (DAQ).(40)

Non-self-reporting or proxy reporting tools/methods included retrospective review of
progress notes and clinical care flow sheets,(28, 31) observer three-grade rating,(22) Support
Team Assessment Schedule (STAS-J),(24, 29, 33, 38) respiratory rate,(25) and the Comfort
Assessment in Dying with Dementia (CAD-EOLD).(37) Three retrospective chart reviews did
not report dyspnea measurement tool assessments; they evaluated opioid infusion patterns for
treating pain and dyspnea at end of life,(23) signs, symptoms, and treatments before death,(26)
and dyspnea, pain and cancer as predictors of increased opioid dosing in the final week of
life.(27)

Study Outcomes
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Morphine

Morphine was the most studied opioid in thirteen of the twenty-three studies. Morphine
showed significant relief of dyspnea intensity when administered alone, (25, 40, 42) and in
combination with other opioids.(29, 34) Significant improvement in dyspnea scoring was
documented with morphine administration for self-reporting (25, 34, 40, 42) and non-selfreporting patients.(24, 29) Many studies based initial morphine dose and/or dose titration on
patients’ prior opioid dosing, dyspnea intensity and patient performance, or side effects, instead
of a predetermined prescribed or protocol dosage regimen. Additional incremental morphine
dosing was documented in only one study of patients undergoing palliative care and was onesixth of the total daily dose given every fifteen minutes as needed,(34) while two other studies
reported the administration of bolus dosing without describing the regimen.(23, 36)
Concomitant morphine with a corticosteroid was administered in one study and demonstrated
significant dyspnea relief, (24) however the combination was not compared to morphine
administration alone.

Non-significant improvement in dyspnea scores was documented in patients with severe
Interstitial Pneumonia after oral and intravenous morphine administration,(32) however dyspnea
efficacy was evaluated as inadequate.

Positive clinical outcomes were reported in four

studies,(30, 31, 36, 38) Parenteral morphine doses for effective dyspnea relief in the studies
varied with patients’ opioid tolerance.(23, 31, 32, 34, 36, 38, 40, 42) Studies including both
opioid naïve and tolerant patients reported variable initial morphine doses. One study titrated as
needed for respiratory comfort, to a median initial dose of 6mg/day (opioid naïve patients) to
12mg/day (opioid tolerant patients).(31) The second study described a two-fold dose increase
initiated after 48 hours if comfort not initially achieved.(38) A study of solely opioid tolerant
patients initiated intravenous morphine by administering 1to 2 mg morphine intravenous bolus
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doses every 5 to 10 minutes to achieve relief, followed by a mean continuous infusion rate of
5.6 mg/hr.(36)

Hydromorphone

Two investigations demonstrated significant improvement in dyspnea intensity selfreported NRS scores with oral hydromorphone administration.(34, 35) One study evaluated
hydromorphone alone(35) and the second also evaluated morphine, using hydromorphone for
patients with low performance status,(34) titrating opioid doses every four hours, breakthrough
doses as needed (Table 1.). Mean hydromorphone dose administered was 2.5 ± 1.8mg (0.56.0mg) for the single agent hydromorphone study.(35) The study examining both
hydromorphone and morphine reported the mean opioid dose administered as 10.8mg ± 3.8mg
(7.5-15mg) morphine equivalent dose, with a a mean hydromorphone dose of 1.44 mg
administered to low performance patients.(34)

Fentanyl

Of the six studies examining fentanyl,(21, 24, 27, 30, 39, 43) only one study where the
palliative care team initiated fentanyl infusions reported a significant, positive correlation
(r=0.75; p=0.009)) between reduction in categorical dyspnea scores and patient-reported
dyspnea severity at 24 hours post initiation of fentanyl intravenous infusion.(39) In another
study, patients with reduced dyspnea scores had a median fentanyl cumulative dose of
7.5mcg/hr (5-25mcg), compared with 12mcg/hr (5-25mcg) for non-responders.(45) Median 24hour fentanyl doses did not differ significantly (p=0.43), between patient responders (167mcg)
and non-responders (227.5mcg). Another study reported that 76% of patients responded to
intravenous fentanyl, with a higher median dose of 25mcg/hour (12-70mcg).(21) Investigators
determined the initial fentanyl dosage using 30% to 50% of the patient’s existing opioid
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treatment, and titrating by 30% to 50% every 24 hours, with breakthrough doses of 10%
administered every 30 minutes as needed.

Concomitant fentanyl and corticosteroid use did not show a significant change in
Support Team Assessment Schedule scores in another study.(24) Single dose administration
of transmucosal fentanyl 200 to 400mcg as lozenges reduced Visual Analog Scale dyspnea
scores by at least 50% within 30 minutes in four patients.(43) During a study of the effect of
various opioids on dyspnea, intravenous fentanyl was administered to6.3% of patients
evaluated 7 days before death, 15.7% of patients 3 days prior, and 1.9% of patients one day
prior .(27) At one day prior to death, 88.7% of patients were receiving morphine. Opioid doses
were converted to oral morphine equivalents. The rationale for changing opioids in this
retrospective study was not provided. A palliative care study evaluated intravenous fentanyl
and morphine unspecified dosing regimens during hospital admission. Self-reported dyspnea
scores were reported for patients discharged alive, however 61.4% of patients died during the
admission.(30)

Oxycodone

Concomitant oral or intravenous administration of oxycodone with oral or intravenous
corticosteroids did not demonstrate significant decreases in Support Team Assessment
Schedule dyspnea scores (P = 0.68).(24) In a case series describing patients with end of life
dyspnea receiving morphine and other opioids, continuous subcutaneous infusion of oxycodone
6 mg/day in one patient with renal dysfunction significantly decreased Support Team
Assessment Schedule dyspnea scores (p<.001).(29) Oxycodone administered via continuous
intravenous infusion palliated dyspnea assessed by Numeric Rating Scale, Visual Analog Scale,
or observer rating, in 88.6% of patients, with an initial mean basal dose of 25.1mg/day (4.884.6mg) and a final mean maintenance dose of 61.8mg/day (3.8-192mg).(22) In this study,
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bolus doses were also given as needed on an average of 2.1 (0-6.4) times daily, resulting in a
mean total oxycodone dose 664.2mg (12-4616.2mg). A lower median initial oxycodone dose
(6mg/day; 2-12mg) and maintenance dose equal to 12mg/day (0-24) provided a patient
response rate of 68.4%.(33) With this lower oxycodone dosage, two of nineteen patients
experienced significant relief of dyspnea. Oxycodone intravenous infusion at an unspecified
dose was administered during the study (which converted all administered opioids to oral
morphine equivalents) for 8.3% of patients evaluated 7 days before death, 2% of patients 3
days prior, and 1.9% of patients one day prior to death.(27) Overall, oral morphine equivalents
increased for younger patients and for those with lowdoses of opioids to relieve dyspnea at 7
days prior to death; there was no evaluation of the specific effect of oxycodone. Currently,
parenteral oxycodone formulations are not available in the U.S.

Discussion

The examined studies contribute to the evidence surrounding opioid use at end of life,
however, consensus on standardization for treatment remains to be discovered. In the existing
evidence, challenges persist in conducting opioid research for the relief of dyspnea at end of
life. The variety of opioids studied, routes of administration, patient populations, end of life
timeframes, and dyspnea measurement assessment and re-assessment tools demonstrate a
need for further investigation.

To achieve symptom management, the symptom first must be recognized. Dyspnea
continues to be underrecognized by hospital staff.(28) As dyspnea at end of life is generally
managed in a medical setting, this is the first obstacle in achieving respiratory comfort.
Dyspnea under-recognition is subsequently followed by opioid underuse, as undocumented
symptoms may go untreated. Opioid underuse in the last three days of life is greater in patients
with dyspnea than patients with pain, an additional challenge in conducting dyspnea
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research.(37) Inconsistencies in documentation and deficiencies in describing symptoms create
limitations for appropriate evaluation and management.(23, 26) Lack of knowledge and
experience in treating dyspnea at end of life may play a role in under-recognition and undertreatment.(37) Early palliative care involvement can help educate patients, families and staff, as
patients suffering from dyspnea having palliative care consults receive more orders for opioids
as a first-line treatment than those without a palliative care team.(28) Palliative care orders
contain detailed instructions for symptom specific opioid administration.
As self-report is deemed the “gold standard”, numerous studies used self-reporting tools
for dyspnea assessment. Self-report evaluation tools are applicable early in palliative care but
not feasible when end-of-life approaches.(3) Decreased consciousness is expected with the
dying process. Excluding non-self-reporting patients decreases generalization to the end-of-life
patient population. Proxy report is often inaccurate and unreliable,(46, 47) therefore the
Respiratory Distress Observation Scale (RDOS) or other appropriate tool is needed for
evaluation and re-evaluation of dyspnea . Respiratory distress is the observed corollary to selfreported dyspnea (6). The Respiratory Distress Observation Scale, is a reliable and valid tool
for measuring the presence and intensity of respiratory distress in adults unable to self-report
dyspnea (48-50). Consistent use of the Respiratory Distress Observation Scale assists
clinicians in the appropriate identification of this difficult symptom, leading to improved
documentation, treatment, and symptom relief. Use of a validated and reliable tool in clinical
practice and in research will improve understanding of symptom relief and opioid efficacy to
develop treatment consensus end-of-life patients.
The period of “end of life” is poorly defined,(51) complicating end of life research.
Palliative care can range from days to several years, depending on the patient and the
promptness of initiation. In this highly variable timeframe, symptom severity and patient ability
to relay intensity can vary. Dyspnea is a predictor of increased oral morphine equivalent dose
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administration in the final seven days of life.(27) Mean dyspnea score two days before death is
significantly higher when compared to scores at admission, even with morphine administration,
indicating refractory dyspnea.(52) Continuous morphine infusion rates at time of death were
demonstrated to be considerably higher when compared to rate at initiation, also supporting the
nature of refractory dyspnea,(23) During this period, consciousness declines limiting the option
of using self-administered or oral opioids. A universally accepted definition of the end-of-life
timeframe will provide greater insight into this specific period of dyspnea management.

The challenges with dyspnea recognition, evaluation and reporting may contribute to the
variability in opioid use and dosing reflected in the end of life literature. A consensus on opioid
selection and dosage regimen has not been established, however dyspnea management
guidelines exist with recommendations on initial dosing and dosing adjustments for
morphine,(11) oxycodone, hydromorphone and fentanyl(1) for oral and intravenous
administration in opioid naïve patients. Recommendations for opioid tolerant patients include an
initial dose increase of 25% to 50%,(11) as these patients often require higher and more
individualized dosing.(1) The studies which described initial dosing of oral and intravenous
opioids generally used dosage regimens recommended by the American Thoracic Society.(1)
Subcutaneous, transmucosal, and nebulized dosage regimens could not be evaluated as there
are no current recommendations for use in dyspnea yet were within the usual dosage ranges for
pain.(53)

Of the included studies, differing opioid dosage regimens were evaluated. One study
found one-quarter of regular opioid dose to be an efficient supplemental dose for dyspnea relief
for up to four hours in patients with low to moderate initial dyspnea intensity.(41) Higher
intensity scoring patients would require increased dosing and careful monitoring. Matsuda et al.
showed that low dose continuous subcutaneous morphine with titration to patient comfort
decreased dyspnea intensity, but numeric rating scale scores remained in a moderate range,
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further supporting the requirement to increase/individualize opioid dosages to achieve patient
comfort and manage acute exacerbation.(25) Murakami confirmed a significant decrease in
dyspnea intensity scores with low-dose opioid use with no discussion of increased dosing
requirements for opioid tolerant patients or those with acute exacerbation.(29) Varying degrees
of renal/hepatic insufficiency, CYP metabolizer status, interacting medications, and previous
opioid exposure affect opioid dosage requirements and clinical response.(54) On the contrary,
Maeda and Hayakawa, in a trial of concomitant opioid and corticosteroid use, were unable to
identify a significant relationship between specific morphine and fentanyl dosing and dyspnea
relief.(24) The variation in opioid use, route of administration, dosing, assessments, and the
heterogeneous patient populations, confounding comorbid conditions, and possible effect of
other treatments, limits conclusions for specific opioid dosage regimen recommendations.

Routes of opioid administration varied, but were prominently enteral and parenteral, with
one study, which included nebulized morphine. Studies using nebulized opioids in the specific
end of life population are limited, especially for advanced patients unable to self-report dyspnea
scores. Claustrophobia from the face mask has been reported,(40) resulting in clinician
hesitancy to use this method of opioid administration.(55) Among patients able to provide selfreport, nebulized morphine alleviated dyspnea with little to no systemic side effects.(40, 56-59)
There are no reports of bronchospasm, secondary to local airway irritation in studies of
nebulized morphine for terminal dyspnea. Patients with poorly controlled asthma may be more
susceptible to bronchospasm caused by morphine mediated histamine release into the
airways.(56) Nebulized hydromorphone was shown as safe and effective for dyspnea
management in patients with advanced cancer and hypersensitivity to nebulized morphine,
.(60) Doses of 4mg hydromorphone in 2mL of sterile water,(60) or 5mg hydromorphone in 3mL
of saline(61) administered via nebulization produced rapid improvement in breathlessness in
patients with advanced cancer.(60, 61) Nebulized fentanyl, 25mcg in 2mL of saline,
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demonstrated improvements in breathing for cancer patients,(62, 63) and decreased respiratory
rate and improved oxygenation, although results were inconclusive when compared to
placebo.(62)

In addition, the reviewed studies have other limitations, which decrease generalization of
findings. Numerous studies were retrospective reviews, conducted in a single-center with a
small sample size. There was limited evaluation of patient age, body composition, opioid
metabolism and elimination, renal and hepatic function, which affect the pharmacokinetics and
pharmacodynamics of opioids administered for the relief of dyspnea at end of life.(64)
Murakami reported respiratory depression in an opioid tolerant patient with low body weight
following low-dose opioid administration,(29) emphasizing the need for individualization of
opioid dose.

Lin et al. demonstrated a negative association with glomerular filtration rate (GFR) and
the number of continuous morphine infusion rate changes (r=-0.18; p,0.01).(23) Patients with
glomerular filtration rate greater than 30 ml/min also received more intravenous morphine
boluses. Those with glomerular filtration rate less than 30 ml/min did show any difference in
length of morphine infusion, 24-hour morphine dosage equivalent, or number of administered IV
bolus doses (p>0.05).(23) Clemens and Klaschik reported that oral hydromorphone relieves
dyspnea in patients with renal impairment or morphine intolerance(29, 34, 35). Oral
administration of opioids may not be practical during later stages of terminal treatment.
However, equianalgesic opioid conversions are readily available for convenient administration
via the parenteral route.(65) Hydromorphone undergoes hepatic metabolism to small amounts
of active metabolites, presenting an alternative to morphine for patients with renal
insufficiency(66) or those experiencing morphine induced cognitive impairment/
drowsiness/nausea.(67) Opioid rotation in palliative care to achieve relief of symptoms or
manage opioid adverse effects is well documented.(68)
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Yamamoto et al. reported that intravenous oxycodone is a safer option than morphine for
dyspnea in cancer patients with renal impairment, however, the investigators reported difficulties
recommending use for patients with hepatic impairment (33) In severe hepatic insufficiency,
oxycodone initial doses should be reduced to 30% to 50% of the usual starting dose.(69) As
hepatic insufficiency decreases opioid clearance, initial opioid dosages must be low, with
extended dosing intervals to avoid accumulation and adverse effects.(69) Changes in the
pharmacokinetics, pharmacodynamics and pharmacogenomics of opioids at the end of life,
complicated by comorbid conditions require an interprofessional approach.

Risk of Bias

Of the 23 included studies, only two were controlled trials with low to moderate risk of
bias (Table 2.). The remaining 21 studies were nonrandomized. Of these, it was determined
that eight had a serious risk of bias and eleven had a critical risk (Table 3.)

Conclusion
This systematic review demonstrates a lack of consistent evidence in the current
literature regarding end-of-life opioid use and does not permit an overall conclusion on opioid
selection, route of administration and dosing, yet supports the limited existing guidelines
regarding opioid administration during this critical period.(9) Opioid selection, route of
administration and dosing regimens must be individualized, until rigorous studies are available
to guide practice. Appropriate dyspnea evaluation and re-evaluation using validated
assessment tools is necessary to demonstrate the efficacy of opioids; and establishing a widely
accepted definition of the end-of-life period is needed to leverage future investigations. Robust
prospective trials will expand the current limited evidence to improve the respiratory comfort for
this extremely vulnerable patient population.
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